drugset / Trial / NCT00811174

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

NCT00811174

Phase 3 Terminated 5 enrolled Octapharma
NaSingle-groupOpen-labelTreatment

Summary

Octagam is a human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in more than 60 countries. This study will evaluate the efficacy, safety and the kinetics of Octagam 10% for replacement therapy in primary immunodeficiency diseases.

Timeline

Start
2009-01
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 300 mg/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 600 mg/kg Intravenous